SHYNDEC(600420)2024-10-09 08:28Financial Performance - Net profit attributable to shareholders of the listed company is expected to be between 925 million yuan and 985 million yuan, representing a year-on-year increase of 64.01% to 74.65%[2] - Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 892 million yuan and 952 million yuan, representing a year-on-year increase of 68.30% to 79.62%[3] - In the same period last year, the company's net profit attributable to shareholders was 563.92 million yuan, and the net profit after deducting non-recurring gains and losses was 530.12 million yuan[4] Market Demand and Sales - The increase in performance is mainly due to strong market demand for penicillin and macrolide APIs, leading to increased sales and improved gross margins in the pharmaceutical intermediates and APIs business segment[5] Cost Control - The company has implemented cost control measures, resulting in a significant year-on-year decrease in period expenses[5]